{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,18]],"date-time":"2026-01-18T11:57:16Z","timestamp":1768737436828,"version":"3.49.0"},"reference-count":42,"publisher":"Wiley","issue":"4","license":[{"start":{"date-parts":[[2010,6,21]],"date-time":"2010-06-21T00:00:00Z","timestamp":1277078400000},"content-version":"vor","delay-in-days":20,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Bipolar Disorders"],"published-print":{"date-parts":[[2010,6]]},"abstract":"<jats:p>Bersudsky Y, Applebaum J, Gaiduk Y, Sharony L, Mishory A, Podberezsky A, Agam G, Belmaker RH. Valnoctamide as a valproate substitute with low teratogenic potential in mania: a double\u2010blind, controlled, add\u2010on clinical trial.\u2028Bipolar Disord 2010: 12: 376\u2013382. \u00a9 2010 The Authors. Journal compilation \u00a9 2010 John Wiley &amp; Sons A\/S.<\/jats:p><jats:p><jats:bold>Objectives:\u2002<\/jats:bold> Valproic acid\u2019s well\u2010known teratogenicity limits its use in women of childbearing age. Valnoctamide is an analog of valproate that does not undergo biotransformation to the corresponding free acid. In mice, valnoctamide has been shown to be distinctly less teratogenic than valproate. Valnoctamide is an anticonvulsant, and we hypothesized that valnoctamide is antimanic.<\/jats:p><jats:p><jats:bold>Methods:\u2002<\/jats:bold> We performed a double\u2010blind, five\u2010week, add\u2010on, controlled trial of valnoctamide in mania. Patients were treated with risperidone at doses of the physician\u2019s discretion. Valnoctamide or placebo was begun at doses of 600\u2003mg\/day and increased to 1200\u2003mg after four days. Weekly ratings by a psychiatrist blind to the study drug were conducted using the Brief Psychiatric Rating Scale (BPRS), the Young Mania Rating Scale (YMRS), and the Clinical Global Impression (CGI).<\/jats:p><jats:p><jats:bold>Results:\u2002<\/jats:bold> Fifteen valnoctamide patients and 17 placebo patients completed at least one post\u2010baseline week and were included in data analysis. In all efficacy measures valnoctamide was more effective than placebo as an add\u2010on to risperidone, using two\u2010way analysis of variance (ANOVA) with time as the within\u2010subject factor. Two\u2010way ANOVA showed a significant effect of time (p\u2003&lt;\u20030.001) and significant interaction between treatment and time (YMRS: p\u2003=\u20030.012; BPRS: p\u2003=\u20030.007; CGI: p\u2003=\u20030.003). Differences between valnoctamide and placebo were significant from week 3 to week 5.<\/jats:p><jats:p><jats:bold>Conclusion:\u2002<\/jats:bold> Valnoctamide could be an important valproate substitute for women of childbearing age with bipolar disorder who may become pregnant.<\/jats:p>","DOI":"10.1111\/j.1399-5618.2010.00828.x","type":"journal-article","created":{"date-parts":[[2010,6,21]],"date-time":"2010-06-21T21:01:15Z","timestamp":1277154075000},"page":"376-382","source":"Crossref","is-referenced-by-count":40,"title":["Valnoctamide as a valproate substitute with low teratogenic potential in mania: a double\u2010blind, controlled, add\u2010on clinical trial"],"prefix":"10.1111","volume":"12","author":[{"given":"Y","family":"Bersudsky","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J","family":"Applebaum","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Y","family":"Gaiduk","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"L","family":"Sharony","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"A","family":"Mishory","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"A","family":"Podberezsky","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"G","family":"Agam","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"RH","family":"Belmaker","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2010,6,21]]},"reference":[{"key":"e_1_2_6_2_2","doi-asserted-by":"publisher","DOI":"10.1007\/BF01870931"},{"key":"e_1_2_6_3_2","first-page":"52","article-title":"Valproic acid teratogenesis","volume":"1","author":"Nau H","year":"1987","journal-title":"ISI Atlas Sci Pharmacol"},{"key":"e_1_2_6_4_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1600-0773.1991.tb01303.x"},{"issue":"9","key":"e_1_2_6_5_2","first-page":"4","article-title":"Treatment of bipolar disorder during pregnancy","volume":"68","author":"Cohen LS","year":"2007","journal-title":"J Clin Psychiatry"},{"key":"e_1_2_6_6_2","doi-asserted-by":"publisher","DOI":"10.1007\/s12325-009-0011-z"},{"key":"e_1_2_6_7_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1399-5618.2007.00565.x"},{"key":"e_1_2_6_8_2","doi-asserted-by":"publisher","DOI":"10.1212\/01.WNL.0000154515.94346.89"},{"key":"e_1_2_6_9_2","doi-asserted-by":"publisher","DOI":"10.1001\/archpsyc.60.4.392"},{"key":"e_1_2_6_10_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0168-3659(99)00037-1"},{"key":"e_1_2_6_11_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0924-9338(00)00513-7"},{"key":"e_1_2_6_12_2","doi-asserted-by":"publisher","DOI":"10.2165\/00003088-199120020-00003"},{"key":"e_1_2_6_13_2","doi-asserted-by":"publisher","DOI":"10.1007\/BF00315032"},{"key":"e_1_2_6_14_2","doi-asserted-by":"publisher","DOI":"10.1002\/jps.2600771003"},{"key":"e_1_2_6_15_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1528-1157.1993.tb02117.x"},{"key":"e_1_2_6_16_2","doi-asserted-by":"publisher","DOI":"10.1016\/0028-3908(85)90028-0"},{"key":"e_1_2_6_17_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0920-1211(97)00095-8"},{"key":"e_1_2_6_18_2","volume-title":"\u03b1\u2010ethyl\u2010\u03b2\u2010methylvaleramide for mental hyperirritability","author":"US Patent 3, 726","year":"1962"},{"key":"e_1_2_6_19_2","doi-asserted-by":"publisher","DOI":"10.1042\/BST0371104"},{"key":"e_1_2_6_20_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.neubiorev.2007.03.002"},{"key":"e_1_2_6_21_2","doi-asserted-by":"publisher","DOI":"10.1523\/JNEUROSCI.4530-04.2005"},{"key":"e_1_2_6_22_2","doi-asserted-by":"publisher","DOI":"10.1074\/jbc.M101287200"},{"key":"e_1_2_6_23_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.biopsych.2004.08.027"},{"key":"e_1_2_6_24_2","first-page":"402","article-title":"Effect of valproate derivatives on human brain myo\u2010inositol\u20101\u2010phosphate (MIP) synthase activity and amphetamine\u2010induced rearing","volume":"59","author":"Shaltiel G","year":"2007","journal-title":"Pharmacol Rep"},{"key":"e_1_2_6_25_2","doi-asserted-by":"publisher","DOI":"10.1192\/bjp.133.5.429"},{"key":"e_1_2_6_26_2","doi-asserted-by":"publisher","DOI":"10.1001\/archpsyc.1979.01780030093009"},{"key":"e_1_2_6_27_2","doi-asserted-by":"publisher","DOI":"10.1001\/archpsyc.1984.01790130061009"},{"key":"e_1_2_6_28_2","doi-asserted-by":"publisher","DOI":"10.1176\/appi.ajp.157.3.463"},{"key":"e_1_2_6_29_2","doi-asserted-by":"publisher","DOI":"10.1192\/bjp.182.2.141"},{"key":"e_1_2_6_30_2","first-page":"753","article-title":"Clinical Study of Valnoctamide on 70 Neuropsychiatric Clinic Patients Undergoing Ambulatory Treatment (in French)","volume":"72","author":"Harl FM","year":"1964","journal-title":"Presse Med"},{"key":"e_1_2_6_31_2","doi-asserted-by":"publisher","DOI":"10.2466\/pr0.1962.10.3.799"},{"key":"e_1_2_6_32_2","first-page":"218","volume-title":"An ECDEU Assessment Manual for Psychopharmacology\u2010Revised","author":"Guy W","year":"1976"},{"key":"e_1_2_6_33_2","doi-asserted-by":"publisher","DOI":"10.1016\/0378-4347(85)80055-4"},{"key":"e_1_2_6_34_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMra035354"},{"key":"e_1_2_6_35_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0009-9236(97)90194-6"},{"key":"e_1_2_6_36_2","doi-asserted-by":"publisher","DOI":"10.1023\/A:1025069519218"},{"key":"e_1_2_6_37_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.nurt.2006.11.007"},{"key":"e_1_2_6_38_2","doi-asserted-by":"publisher","DOI":"10.1176\/appi.ajp.163.2.272"},{"key":"e_1_2_6_39_2","doi-asserted-by":"publisher","DOI":"10.2165\/00003088-200443110-00004"},{"key":"e_1_2_6_40_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa0803531"},{"key":"e_1_2_6_41_2","doi-asserted-by":"publisher","DOI":"10.1176\/appi.ajp.2007.06101639"},{"key":"e_1_2_6_42_2","doi-asserted-by":"publisher","DOI":"10.1176\/appi.ajp.162.8.1546-a"},{"key":"e_1_2_6_43_2","doi-asserted-by":"publisher","DOI":"10.1159\/000314306"}],"container-title":["Bipolar Disorders"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fj.1399-5618.2010.00828.x","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/j.1399-5618.2010.00828.x","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,31]],"date-time":"2023-10-31T01:36:56Z","timestamp":1698716216000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/j.1399-5618.2010.00828.x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2010,6]]},"references-count":42,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2010,6]]}},"alternative-id":["10.1111\/j.1399-5618.2010.00828.x"],"URL":"https:\/\/doi.org\/10.1111\/j.1399-5618.2010.00828.x","archive":["Portico"],"relation":{},"ISSN":["1398-5647","1399-5618"],"issn-type":[{"value":"1398-5647","type":"print"},{"value":"1399-5618","type":"electronic"}],"subject":[],"published":{"date-parts":[[2010,6]]}}}